412 related articles for article (PubMed ID: 35565273)
41. Personalized Cancer Medicine: An Organoid Approach.
Aboulkheyr Es H; Montazeri L; Aref AR; Vosough M; Baharvand H
Trends Biotechnol; 2018 Apr; 36(4):358-371. PubMed ID: 29366522
[TBL] [Abstract][Full Text] [Related]
42. Three-Dimensional Organoids in Cancer Research: The Search for the Holy Grail of Preclinical Cancer Modeling.
Dzobo K; Rowe A; Senthebane DA; AlMazyadi MAM; Patten V; Parker MI
OMICS; 2018 Dec; 22(12):733-748. PubMed ID: 30571609
[TBL] [Abstract][Full Text] [Related]
43. Advances in liver organoids: model systems for liver disease.
Lee J; Mun SJ; Shin Y; Lee S; Son MJ
Arch Pharm Res; 2022 Jun; 45(6):390-400. PubMed ID: 35661984
[TBL] [Abstract][Full Text] [Related]
44. Organoids: An intermediate modeling platform in precision oncology.
Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
[TBL] [Abstract][Full Text] [Related]
45. Patient-Derived Organoids as a Model for Cancer Drug Discovery.
Rae C; Amato F; Braconi C
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801782
[TBL] [Abstract][Full Text] [Related]
46. [Spheroids to organoids: Solid cancer models for anticancer drug discovery].
Alzeeb G; Corcos L; Le Jossic-Corcos C
Bull Cancer; 2022 Jan; 109(1):49-57. PubMed ID: 34848046
[TBL] [Abstract][Full Text] [Related]
47. Organoid models of glioblastoma: advances, applications and challenges.
Zhang C; Jin M; Zhao J; Chen J; Jin W
Am J Cancer Res; 2020; 10(8):2242-2257. PubMed ID: 32905502
[TBL] [Abstract][Full Text] [Related]
48. Cancer modeling meets human organoid technology.
Tuveson D; Clevers H
Science; 2019 Jun; 364(6444):952-955. PubMed ID: 31171691
[TBL] [Abstract][Full Text] [Related]
49. Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine.
Xu H; Jiao Y; Qin S; Zhao W; Chu Q; Wu K
Exp Hematol Oncol; 2018; 7():30. PubMed ID: 30534474
[TBL] [Abstract][Full Text] [Related]
50. Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response.
Spiller ER; Ung N; Kim S; Patsch K; Lau R; Strelez C; Doshi C; Choung S; Choi B; Juarez Rosales EF; Lenz HJ; Matasci N; Mumenthaler SM
Front Oncol; 2021; 11():771173. PubMed ID: 34993134
[TBL] [Abstract][Full Text] [Related]
51. Establishment of an organoid bank of biliary tract and pancreatic cancers and its application for personalized therapy and future treatment.
Saito Y
J Gastroenterol Hepatol; 2019 Nov; 34(11):1906-1910. PubMed ID: 31264257
[TBL] [Abstract][Full Text] [Related]
52. Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line.
Pyo DH; Hong HK; Lee WY; Cho YB
Cancer Biol Ther; 2020 Jun; 21(6):495-502. PubMed ID: 32208894
[TBL] [Abstract][Full Text] [Related]
53. Modeling neoplastic disease with spheroids and organoids.
Zanoni M; Cortesi M; Zamagni A; Arienti C; Pignatta S; Tesei A
J Hematol Oncol; 2020 Jul; 13(1):97. PubMed ID: 32677979
[TBL] [Abstract][Full Text] [Related]
54. Organoids as research models for hepatocellular carcinoma.
Yu JH; Ma S
Exp Cell Res; 2022 Feb; 411(1):112987. PubMed ID: 34942189
[TBL] [Abstract][Full Text] [Related]
55. Organ-on-Chip platforms to study tumor evolution and chemosensitivity.
Dsouza VL; Kuthethur R; Kabekkodu SP; Chakrabarty S
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188717. PubMed ID: 35304293
[TBL] [Abstract][Full Text] [Related]
56. Organoids: a novel modality in disease modeling.
Heydari Z; Moeinvaziri F; Agarwal T; Pooyan P; Shpichka A; Maiti TK; Timashev P; Baharvand H; Vosough M
Biodes Manuf; 2021; 4(4):689-716. PubMed ID: 34395032
[TBL] [Abstract][Full Text] [Related]
57. Establishment of a mouse model of pancreatic cancer using human pancreatic cancer cell line S2-013-derived organoid.
Tanaka C; Furihata K; Naganuma S; Ogasawara M; Yoshioka R; Taniguchi H; Furihata M; Taniuchi K
Hum Cell; 2022 Mar; 35(2):735-744. PubMed ID: 35150409
[TBL] [Abstract][Full Text] [Related]
58. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
Nanki Y; Chiyoda T; Hirasawa A; Ookubo A; Itoh M; Ueno M; Akahane T; Kameyama K; Yamagami W; Kataoka F; Aoki D
Sci Rep; 2020 Jul; 10(1):12581. PubMed ID: 32724113
[TBL] [Abstract][Full Text] [Related]
59. The Central Role of Wnt Signaling and Organoid Technology in Personalizing Anticancer Therapy.
Vincan E; Schwab RHM; Flanagan DJ; Moselen JM; Tran BM; Barker N; Phesse TJ
Prog Mol Biol Transl Sci; 2018 Jan; 153():299-319. PubMed ID: 29389521
[TBL] [Abstract][Full Text] [Related]
60. Microengineered Organ-on-a-chip Platforms towards Personalized Medicine.
Kankala RK; Wang SB; Chen AZ
Curr Pharm Des; 2018; 24(45):5354-5366. PubMed ID: 30799783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
